What is Sales and Marketing Strategy of Daiichi Sankyo Company?

Field-based Key Account Managers, Medical Science Liaisons and market-access teams target academic medical centers and NCI-designated centers in the U.S., EU5 and Japan; buy-and-bill and specialty clinic dynamics deliver the majority of oncology revenue.

U.S. distribution via leading specialty distributors and specialty pharmacies preserves cold-chain integrity, supports prior authorization and financial-assistance programs, and enables next-day delivery—critical as outpatient infusion volumes rose after 2020.

Joint promotion and shared field footprint for ENHERTU (and Dato-DXd upon approvals) across more than 30 markets accelerates formulary access and HCP reach; alliance milestones/royalties reduce fixed SG&A while scaling globally—ENHERTU reached a global annualized run-rate of between $3.5–4.0 billion by FY2024.

Japan’s National Health Insurance, EU hospital tenders and selected APAC tenders drive institutional uptake; pricing, HTA outcomes (for example NICE, HAS decisions) and tender results materially influence time-to-scale and net pricing.

Proprietary DXd platform and a broad pipeline across HER2 and TROP2 create a differentiation halo; repeated ASCO/ESMO late-breakers and guideline inclusions (NCCN/ESMO) support credibility and the Daiichi Sankyo commercial strategy.

Brand messaging emphasizes measurable endpoints (ORR, PFS, OS) and practical access solutions—hub services and financial support—aligning Daiichi Sankyo sales strategy with real-world patient access needs.

Clinical, human-centric visual identity and an evidence-led, compliant tone are applied from congress booths to HCP portals and patient materials, reinforcing trust and rapid safety communication (e.g., ILD risk management).

As ADC competition grows, the brand doubles down on transparent data sharing, safety education and real-world evidence to sustain leadership and support oncology product launch strategy across US and EU markets.

Objective: educate clinicians on the HER2-low category and accelerate adoption in metastatic breast cancer using DESTINY-Breast04 evidence. Channels included ASCO/ESMO plenaries, KOL webinars, HCP portals, targeted programmatic and advocacy partnerships. Results: rapid guideline inclusion (NCCN/ESMO), high HCP engagement, increased HER2 testing and contribution to a multi-billion-dollar global sales run-rate by FY2024.

Objective: broaden ENHERTU use in HER2-mutant NSCLC and prepare the market for Dato-DXd in HR+/HER2- and TNBC. Creative: case-based tumor board series and biomarker pathway content. Channels: congresses, peer exchanges, EMR-triggered education and payer dossiers. Results: accelerated formulary wins, increased referrals and in-market share gains in targeted NSCLC subpopulations.

Objective: reinforce safe use of ADCs via monitoring algorithms, nurse-led training and patient symptom trackers. Channels: HCP toolkits, infusion center signage and digital modules. Outcomes: improved adherence to monitoring protocols, sustained prescriber confidence and strengthened brand trust supported by pharmacovigilance communications.

Objective: pre-approval demand shaping for breast and lung indications. Creative: TROP2 disease-state education, ADC differentiation and patient journey tools. Channels: ESMO/ASCO data waves, KOL roadshows, CRM omnichannel and payer advisory boards. Early indicators: high unaided awareness, payer preparedness with provisional criteria and strong intent-to-prescribe; collaboration with AstraZeneca amplified reach.